Literature DB >> 35396345

Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?

Gemma L Kelly1,2, Andreas Strasser3,4, Annabella F Thomas1,2.   

Abstract

The tumour suppressor TP53 is a master regulator of several cellular processes that collectively suppress tumorigenesis. The TP53 gene is mutated in ~50% of human cancers and these defects usually confer poor responses to therapy. The TP53 protein functions as a homo-tetrameric transcription factor, directly regulating the expression of ~500 target genes, some of them involved in cell death, cell cycling, cell senescence, DNA repair and metabolism. Originally, it was thought that the induction of apoptotic cell death was the principal mechanism by which TP53 prevents the development of tumours. However, gene targeted mice lacking the critical effectors of TP53-induced apoptosis (PUMA and NOXA) do not spontaneously develop tumours. Indeed, even mice lacking the critical mediators for TP53-induced apoptosis, G1/S cell cycle arrest and cell senescence, namely PUMA, NOXA and p21, do not spontaneously develop tumours. This suggests that TP53 must activate additional cellular responses to mediate tumour suppression. In this review, we will discuss the processes by which TP53 regulates cell death, cell cycling/cell senescence, DNA damage repair and metabolic adaptation, and place this in context of current understanding of TP53-mediated tumour suppression.
© 2022. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35396345      PMCID: PMC9090748          DOI: 10.1038/s41418-022-00996-z

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   12.067


  151 in total

Review 1.  Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis.

Authors:  D Westphal; R M Kluck; G Dewson
Journal:  Cell Death Differ       Date:  2013-10-25       Impact factor: 15.828

2.  p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

Authors:  Liz J Valente; Daniel H D Gray; Ewa M Michalak; Josefina Pinon-Hofbauer; Alex Egle; Clare L Scott; Ana Janic; Andreas Strasser
Journal:  Cell Rep       Date:  2013-05-09       Impact factor: 9.423

3.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

4.  Evidence for involvement of yeast proliferating cell nuclear antigen in DNA mismatch repair.

Authors:  R E Johnson; G K Kovvali; S N Guzder; N S Amin; C Holm; Y Habraken; P Sung; L Prakash; S Prakash
Journal:  J Biol Chem       Date:  1996-11-08       Impact factor: 5.157

Review 5.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

6.  mTORC1 promotes survival through translational control of Mcl-1.

Authors:  John R Mills; Yoshitaka Hippo; Francis Robert; Samuel M H Chen; Abba Malina; Chen-Ju Lin; Ulrike Trojahn; Hans-Guido Wendel; Al Charest; Roderick T Bronson; Scott C Kogan; Robert Nadon; David E Housman; Scott W Lowe; Jerry Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-29       Impact factor: 11.205

Review 7.  The p53 response to DNA damage.

Authors:  David W Meek
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

8.  Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a).

Authors:  Utz Herbig; Wendy A Jobling; Benjamin P C Chen; David J Chen; John M Sedivy
Journal:  Mol Cell       Date:  2004-05-21       Impact factor: 17.970

9.  Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.

Authors:  Sean P Garrison; John R Jeffers; Chunying Yang; Jonas A Nilsson; Mark A Hall; Jerold E Rehg; Wen Yue; Jian Yu; Lin Zhang; Mihaela Onciu; Jeffery T Sample; John L Cleveland; Gerard P Zambetti
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

10.  Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis.

Authors:  Sarah A Best; Cassandra J Vandenberg; Etna Abad; Lachlan Whitehead; Laia Guiu; Sheryl Ding; Margs S Brennan; Andreas Strasser; Marco J Herold; Kate D Sutherland; Ana Janic
Journal:  Cell Death Dis       Date:  2020-10-20       Impact factor: 8.469

View more
  4 in total

1.  Exploring the future of research in the Tp53 field.

Authors:  Arnold J Levine
Journal:  Cell Death Differ       Date:  2022-04-05       Impact factor: 12.067

2.  HS-1793 inhibits cell proliferation in lung cancer by interfering with the interaction between p53 and MDM2.

Authors:  Chungun Lim; Peter C W Lee; Sungbo Shim; Sung-Wuk Jang
Journal:  Oncol Lett       Date:  2022-07-01       Impact factor: 3.111

3.  A p53 transcriptional signature in primary and metastatic cancers derived using machine learning.

Authors:  Faeze Keshavarz-Rahaghi; Erin Pleasance; Tyler Kolisnik; Steven J M Jones
Journal:  Front Genet       Date:  2022-08-29       Impact factor: 4.772

4.  Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.

Authors:  Viktor Hlaváč; Petr Holý; Radka Václavíková; Lukáš Rob; Martin Hruda; Marcela Mrhalová; Petr Černaj; Jiří Bouda; Pavel Souček
Journal:  Life Sci Alliance       Date:  2022-10-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.